FDA Approves Atacicept for IgA Nephropathy - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Atacicept for IgA Nephropathy

The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.

  • By

  • Kathryn Wighton

  • July 7, 2026

  • 3 min

Share

Clinical Scorecard: FDA Approves Atacicept for IgA Nephropathy

At a Glance

CategoryDetail
ConditionPrimary Immunoglobulin A Nephropathy
Key MechanismsTargets B-cell activating factor and A Proliferation Inducing Ligand, proteins involved in immune cell survival and maturation.
Target PopulationAdults with primary IgA nephropathy at risk for disease progression.
Care SettingClinical trial and outpatient management.

Key Highlights

  • Atacicept is the first approved therapy for primary IgA nephropathy.
  • Demonstrated a 46% reduction in proteinuria at 9 months compared to placebo.
  • Accelerated approval granted based on proteinuria reduction.
  • Patients must be evaluated for infections before treatment.
  • Ongoing clinical trial required to verify long-term kidney function benefits.

Guideline-Based Recommendations

Diagnosis

  • Biopsy-confirmed primary IgA nephropathy.

Management

  • Monitor for proteinuria and assess kidney function.

Monitoring & Follow-up

  • Evaluate for active infections before treatment initiation and during therapy.

Risks

  • Increased risk of infections and injection site reactions.

Patient & Prescribing Data

Adults with biopsy-confirmed primary IgA nephropathy.

Atacicept administered subcutaneously at 150 mg once weekly.

Clinical Best Practices

  • Do not administer live vaccines within 30 days prior to treatment or during treatment.
  • Monitor patients for signs of infection during therapy.

Related Resources & Content

Original Source(s)

FDA Approves Atacicept for IgA Nephropathy

  • by Kathryn Wighton

  • July 7, 2026

Related Content

Inside the hip osteoarthritis microbiome

Investigators compared intra-articular microbial profiles and predicted metabolic pathways in patients with hip osteoarthritis and nonarthritic controls.

Can Controlled Breathing Reduce Substance Craving?

A systematic review and meta-analysis found small, consistent reductions in craving across substance use disorders, while evidence for withdrawal symptoms and substance dependence remained limited.

Medical Oddities: A fowl cause of urinary obstruction

A rogue chicken bone, stalled sweat, yoga for IBS, and L-theanine for sleep is break room fodder this week.